{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:45:59Z","timestamp":1775947559555,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ANZ Journal of Surgery"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cardiovascular disease guidelines recommend that patients with established peripheral artery disease (PAD) are prescribed antihypertensive, lipid\u2010lowering, and antiplatelet medication to reduce cardiovascular ischaemic events. However, the prescribing of these medications for patients with PAD within New Zealand (NZ) remains undefined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective observational cohort study of patients in the Midland region of NZ, that underwent PAD\u2010related percutaneous and surgical intervention between 1st January 2010 and 31st December 2021. Patient level data was collected. The primary outcome was prescribing of cardioprotective medications either before or within 1 year of incident procedure. Secondary outcome was overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 2547 patients included. Antihypertensive prescription occurred in 80.7%, lipid\u2010lowering in 77.4% and antithrombotic in 89.9%. Concomitant ischaemic heart disease increased prescription of cardioprotective medications. Women were prescribed less lipid\u2010lowering medication compared to men. M\u0101ori men were prescribed less antiplatelet medication compared to non\u2010M\u0101ori men. On univariate analysis lipid\u2010lowering and antiplatelet medication showed survival advantage, while antihypertensive and anticoagulation did not. After adjustment for age, sex, end stage renal failure and presence of chronic limb\u2010threatening ischaemia, best medical therapy was associated with better survival (HR 0.88, 95% CI 0.79\u20130.98, <jats:italic>P<\/jats:italic>\u2009=\u20090.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights areas of deficiency in prescribing of cardioprotective medication in this high\u2010risk group. These could be targets for national quality improvement initiatives.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ans.18580","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T04:35:00Z","timestamp":1687926900000},"page":"2376-2381","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The prescribing of cardioprotective medications and the impact on survival for patients with peripheral artery disease that undergo intervention"],"prefix":"10.1111","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-2810","authenticated-orcid":false,"given":"Odette","family":"Hart","sequence":"first","affiliation":[{"name":"Department of Surgery The University of Auckland  Auckland New Zealand"},{"name":"Department of Vascular Surgery Waikato District Health Board  Hamilton New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Surgery The University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-8433","authenticated-orcid":false,"given":"Manar","family":"Khashram","sequence":"additional","affiliation":[{"name":"Department of Surgery The University of Auckland  Auckland New Zealand"},{"name":"Department of Vascular Surgery Waikato District Health Board  Hamilton New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123303"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.01.067"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.008"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020333"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.868505"},{"key":"e_1_2_10_7_1","volume-title":"Cardiovascular Disease Risk Assessment and Management for Primary Care","author":"Ministry of Health","year":"2018"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.02.016"},{"key":"e_1_2_10_9_1","unstructured":"National Institute for Health and Care Excellence (NICE).Surveillance report 2018\u2014Cardiovascular disease: risk assessment and reduction including lipid modification (2014) NICE guideline CG181. NICE;2018."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.003954"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.11.056"},{"key":"e_1_2_10_12_1","article-title":"Baseline modern medical management in the BEST\u2010CLI trial","volume":"17","author":"Menard MT","year":"2023","journal-title":"J. Vasc. Surg."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2020.05.001"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ans.16469"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X20987612"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X15574321"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.07.130"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1421"},{"key":"e_1_2_10_20_1","unstructured":"Best Practice Advocacy Centre New Zealand (BPACnz).Prescribing statins to reduce cardiovascular risk;2021."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.09.018"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.05.115"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"e_1_2_10_24_1","first-page":"805","article-title":"Prioritising CVD prevention therapy: absolute risk versus individual risk factors","volume":"41","author":"Doust J","year":"2012","journal-title":"Aust. Fam. Physician"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000208"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32409-1"},{"key":"e_1_2_10_27_1","volume-title":"Towards a Theory of Change","author":"Pharmaceutical Management Agency","year":"2019"},{"key":"e_1_2_10_28_1","volume-title":"Equitable Access to Medicines Via Primary Healthcare: A Review of the Literature","author":"Carswell S","year":"2018"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2022.02.007"}],"container-title":["ANZ Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ans.18580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T04:34:51Z","timestamp":1697603691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ans.18580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/ans.18580"],"URL":"https:\/\/doi.org\/10.1111\/ans.18580","archive":["Portico"],"relation":{},"ISSN":["1445-1433","1445-2197"],"issn-type":[{"value":"1445-1433","type":"print"},{"value":"1445-2197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"2023-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}